Effects of SGLT2 inhibitors on anemia in patients with diabetes and chronic kidney disease: A population-based cohort study using target trial emulation framework

被引：0
|
作者：
Hu, Jia-Chian [1 ]
Shao, Shih-Chieh [2 ]
Tsai, Daniel Hsiang-Te [1 ]
Chuang, Albert Tzu-Ming [1 ]
Liu, Kuan-Hung [3 ]
Lai, Edward Chia-Cheng [1 ]
机构：
[1] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Coll Med, Tainan, Taiwan
[2] Keelung Chang Gung Mem Hosp, Keelung, Taiwan
[3] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
160
引用
收藏
页码：65 / 65
页数：1
相关论文
共 50 条
  • [1] The effects of the SGLT2 inhibitors on the Japanese type 2 diabetes patients with chronic kidney disease
    Kobayashi, K.
    Sato, K.
    Hatori, N.
    Miyakawa, M.
    Toyoda, M.
    DIABETOLOGIA, 2017, 60 : S418 - S418
  • [2] Comparison of Anemia Outcomes between SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Patients with Chronic Kidney Disease: Multi-institutional Cohort Study with Target Trial Emulation in Taiwan
    Shao, Shih-Chieh
    Hu, Jia-Chian
    Tsai, Daniel Hsiang-Te
    Chuang, Albert Tzu-Ming
    Liu, Kuan-Hung
    Lai, Edward Chia-Cheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 537 - 537
  • [3] The Kidney Effects of the SGLT2 Inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
    Kobayashi, Kazuo
    Toyoda, Masao
    Hatori, Nobuo
    Sakai, Hiroyuki
    Furuki, Takayuki
    Tamura, Kouichi
    Miyakawa, Masaaki
    DIABETES, 2019, 68
  • [4] Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease
    Scheen, Andre J.
    Delanaye, Pierre
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2022, 17 (01) : 35 - 46
  • [5] Incidence of anemia in patients with chronic kidney disease - A population-based cohort study
    Vestergaard, Soren V.
    Heide-Jorgensen, Uffe
    van Haalen, Heleen
    James, Glen
    Hedman, Katarina
    Birn, Henrik
    Thomsen, Reimar W.
    Christiansen, Christian F.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 82 - 83
  • [6] INCIDENCE OF ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE - A POPULATION-BASED COHORT STUDY
    Vestergaard, Soren Viborg
    Heide-Jorgensen, Uffe
    Van Haalen, Heleen
    James, Glen
    Hedman, Katarina
    Birn, Henrik
    Sorensen, Henrik Toft
    Thomsen, Reimar Wernich
    Christiansen, Christian Fynbo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [7] SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
    Kanduri, Swetha R.
    Kovvuru, Karthik
    Hansrivijit, Panupong
    Thongprayoon, Charat
    Vallabhajosyula, Saraschandra
    Pivovarova, Aleksandra I.
    Chewcharat, Api
    Garla, Vishnu
    Medaura, Juan
    Cheungpasitporn, Wisit
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09)
  • [8] Real-World Use of SGLT2 Inhibitors in Patients with CKD with and without Diabetes: A Population-Based Cohort Study
    Toro, Luis
    Valderrama, Josefa
    Polanco, Diego
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [9] Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
    Scheen, Andre J.
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (03) : 243 - 256
  • [10] Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia
    Packer, Milton
    AMERICAN JOURNAL OF NEPHROLOGY, 2024, 55 (02) : 255 - 259
12345